Changing epidemiology of bacterial meningitis

被引：41

作者：

Dery M.A. ^{[1
]}

Hasbun R. ^{[1
]}

机构：

[1] Infectious Diseases Section, Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112

来源：

Current Infectious Disease Reports | 2007年 / 9卷 / 4期

关键词：

Meningitis; Bacterial Meningitis; Conjugate Vaccine; Invasive Pneumococcal Disease; Meningococcal Disease;

D O I：

10.1007/s11908-007-0047-7

中图分类号：

学科分类号：

摘要：

Immunization against the most common meningeal pathogens is the leading factor associated with decreased incidence of bacterial meningitis in countries where routine vaccination is available. This is most dramatically illustrated by the reduction in the incidence of Haemophilus influenzae type b meningitis. The incidence of bacterial meningitis has decreased by 55% since the introduction of the H. influenzae type b conjugate vaccine in 1990. H. influenzae occurred primarily in children younger than 5 years of age, and so the median age of patients with bacterial meningitis has now increased to 39 years of age in the United States, and the leading pathogen is currently Streptococcus pneumoniae. Three other control measures (ie, universal screening and antibiotic prophylaxis of pregnant women for Group B streptococci and the implementation and availability of the S. pneumoniae and Neisseria meningitidis conjugate vaccines) have likely further decreased the incidence of these meningeal pathogens. Lastly, the worldwide emergence of multidrug-resistant pneumococci has complicated the empiric therapy of bacterial meningitis. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：301 / 307

页数：6

共 48 条

[1]

Wenger J.D., Hightower A.W., Facklam R.R., Et al., Bacterial meningitis in the United States, 1986: Report of a multistate surveillance study. The Bacterial Meningitis Study Group, J Infect Dis, 162, pp. 1316-1323, (1990)

[2]

Schuchat A., Robinson K., Wenger J.D., Et al., Bacterial meningitis in the United States in 1995. Active Surveillance Team, N Engl J Med, 337, pp. 970-976, (1997)

[3]

Thigpen M.C., Rosenstein N., Whitney C., Et al., Bacterial meningitis in the United States: 1998-2003, Presented at the 43rd Annual Infectious Diseases Society Meeting, (2005)

[4]

Kainer M., McCauley T., Craig A.S., Prevention of early-onset group B streptococcal disease in newborn, Tenn Med, 98, pp. 232-233, (2005)

[5]

Ruhe J., Myers L., Mushatt D., Hasbun R., High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: Identification of a low-risk subgroup, Clin Infect Dis, 38, pp. 508-514, (2004)

[6]

Progress toward elimination of Haemophilus influenzae Type b invasive disease among infants and children - United States, 1998-2000, MMWR Morb Mortal Wkly Rep, 51, pp. 234-237, (2002)

[7]

Peltola H., Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates, Clin Microbiol Rev, 13, pp. 302-317, (2000)

[8]

Black S.B., Shinefield H.R., Fireman B., Et al., Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group, Pediatr Infect Dis J, 10, pp. 97-104, (1991)

[9]

Santosham M., Wolff M., Reid R., Et al., The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitides outer-membrane protein complex, N Eng J Med, 324, pp. 1767-1772, (1991)

[10]

Takala A.K., Eskola J., Leinonen M., Et al., Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine, J Infect Dis, 164, pp. 982-986, (1991)

← 1 2 3 4 5 →